Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

被引:58
作者
Dandekar, PK
Maglio, D
Sutherland, CA
Nightingale, CH
Nicolau, DP
机构
[1] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06102 USA
[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA
[3] Hartford Hosp, Res Off, Hartford, CT 06102 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 08期
关键词
D O I
10.1592/phco.23.8.988.32878
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To assess the pharmacokinetics of meropenem administered as a 3-hour infusion. Design. Randomized, crossover, open-label study Setting. Clinical research center. Subjects. Six healthy adult male volunteers. Intervention. Each subject received meropenem 0.5 or 2 g every 8 hours as a 3-hour infusion for three doses and then crossed over to the other dosage regimen. Measurement and Main Results. Pharmacokinetic parameters of both regimens were compared, and no significant differences between 0.5- and 2-g doses for the dose-independent parameters (half-life, clearance, and volume of distribution at steady state) were observed. The regimens displayed dose proportionality and were consistent with that of a traditional 0.5-hour infusion. The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of stability at room temperature stability Conclusion. Prolonging the percentage of time above the minimum inhibitory concentration is a feasible option with meropenem; however, further studies are needed to quantify how this increase translates to efficacy
引用
收藏
页码:988 / 991
页数:4
相关论文
共 12 条
  • [1] *ASTR PHARM, 2001, MERR MER PACK INS
  • [2] RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS
    BODEY, GP
    KETCHEL, SJ
    RODRIGUEZ, V
    [J]. AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) : 608 - 616
  • [3] Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients
    Bui, KQ
    Ambrose, PG
    Nicolau, DP
    Lapin, CD
    Nightingale, CH
    Quintiliani, R
    [J]. CHEMOTHERAPY, 2001, 47 (03) : 153 - 156
  • [4] CRAIG W, 1993, 33 INT C ANT AG CHEM, P135
  • [5] CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS
    CRAIG, WA
    EBERT, SC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) : 2577 - 2583
  • [6] High-performance liquid chromatographic assay for meropenem in serum
    Elkhaili, H
    Niedergang, S
    Pompei, D
    Linger, L
    Leveque, D
    Jehl, F
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 686 (01): : 19 - 26
  • [7] Stability of meropenem in a portable infusion device in a cold pouch
    Grant, EM
    Zhong, MK
    Ambrose, PG
    Nicolau, DP
    Nightingale, CH
    Quintiliani, R
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (10) : 992 - 995
  • [8] Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: Case report and review
    Kwa, AL
    Tam, VH
    Rybak, MJ
    [J]. PHARMACOTHERAPY, 2001, 21 (08): : 998 - 1002
  • [9] Comparative pharmacokinetics of the carbapenems - Clinical implications
    Mouton, JW
    Touw, DJ
    Horrevorts, AM
    Vinks, AATMM
    [J]. CLINICAL PHARMACOKINETICS, 2000, 39 (03) : 185 - 201
  • [10] MEROPENEM CLINICAL PHARMACOKINETICS
    MOUTON, JW
    VANDENANKER, JN
    [J]. CLINICAL PHARMACOKINETICS, 1995, 28 (04) : 275 - 286